Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis

Abstract

In this retrospective assessment of consecutive myelofibrosis patients treated with lenalidomide or thalidomide, thalidomide-treated patients were more often thrombocytopenic and had higher-risk disease than lenalidomide-treated patients. Clinical benefit rates were similar and frequently due to anemia benefit. Splicing mutations were common in both cohorts, though thalidomide-treated patients were more likely to harbor high-risk splicing mutations.